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Abstract 
Background: Data regarding the long‑term clinical outcomes in patients with insulin‑treated type 2 diabetes melli‑
tus (ITDM) revascularized by either coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) 
are still controversial. We sought to compare the long‑term (≥1 year) adverse clinical outcomes in patients with ITDM 
who underwent revascularization by either CABG or PCI.
Methods: Randomized Controlled Trials (RCTs) comparing the long‑term clinical outcomes in patients with ITDM 
and non‑ITDM revascularized by either CABG or PCI were searched from electronic databases. Data for patients with 
ITDM were carefully retrieved. Odd Ratio (OR) with 95 % confidence interval (CI) was used to express the pooled effect 
on discontinuous variables and the pooled analyses were performed with RevMan 5.3.
Results: Six RCTs involving 10 studies, with a total of 1297 patients with ITDM were analyzed (639 patients from 
the CABG group and 658 patients from the PCI group). CABG was associated with a significantly lower mortality rate 
compared to PCI with OR: 0.59, 95 % CI 0.42–0.85; P = 0.004. Major adverse cardiovascular and cerebrovascular events 
as well as repeated revascularization were also significantly lower in the CABG group with OR: 0.51, 95 % CI 0.27–0.99; 
P = 0.03 and OR 0.34, 95 % CI 0.24–0.49; P < 0.00001 respectively. However, compared to PCI, the rate of stroke was 
higher in the CABG group with OR: 1.41, 95 % CI 0.64–3.09; P = 0.40, but this result was not statistically significant.
Conclusion: CABG was associated with significantly lower long‑term adverse clinical outcomes compared to PCI in 
patients with ITDM. However, due to an insignificantly higher rate of stroke in the CABG group, further researches with 
a larger number of randomized patients are required to completely solve this issue.
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Background
Type 2 Diabetes mellitus (T2DM) and Coronary Artery 
Disease (CAD) are two important and prevalent chronic 
disorders which often co-exist [1]. Patients with T2DM 
have been found to have more adverse clinical out-
comes compared to non-diabetic (NDM) patients after 
Percutaneous Coronary Intervention (PCI). Moreover, 
prognosis after coronary angioplasty is even worse in 
insulin-treated T2DM (ITDM) patients when compared 
to non-insulin treated T2DM (NITDM) patients [2, 3].
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Many studies have shown that revascularization per-
formed using Coronary Artery Bypass Surgery (CABG) 
appears to be a better option compared to PCI in patients 
with T2DM, particularly in conditions such as multi-ves-
sel CAD, chronic total occlusion and so on. For example, 
earlier reports based on data from the CARDia (Coro-
nary Artery Revascularization in Diabetes) trial [4] and 
the 5-year results of the SYNTAX trial [5] indicated sig-
nificantly higher rates of Major Adverse Cardiovascular 
and Cerebrovascular Events (MACCEs) associated with 
PCI compared to CABG in patients with T2DM.
However, even if PCI is expected to be associated with 
worse clinical outcomes in patients with ITDM, data 
regarding the long-term adverse clinical outcomes in 
similar patients revascularized by either CABG or PCI 
are still controversial. To further support this point, 
results from the FREEDOM trial showed no significant 
difference in the magnitude of CABG versus PCI treat-
ment effect in patients with ITDM [2].
Therefore, to solve this issue, we aim to compare the 
long-term adverse clinical outcomes in patients with 
ITDM revascularized by either CABG or PCI.
Methods
Data sources and search strategy
Medline and EMBASE were searched for Randomized 
Controlled Trials (RCTs) comparing CABG with PCI 
in patients with both ITDM and NITDM by typing the 
words ‘diabetes mellitus, coronary artery bypass sur-
gery and percutaneous coronary intervention’. To fur-
ther enhance this search, the abbreviations ‘DM, CABG 
and PCI’ have also been used. References have also been 
checked for relevant RCTs. No language restriction was 
applied.
Inclusion and exclusion criteria
Studies were included if:
(a)  They were RCTs.
(b)  They compared patients with ITDM and NITDM 
revascularized by either CABG or PCI.
(c)   They reported long-term (≥1 year) adverse clinical 
outcomes observed in those patients with ITDM.
Studies were excluded if:
(a)   They were not RCTs (excluded if they were obser-
vational studies, case studies or meta-analyses).
(b)  Data for patients with ITDM could not be retrieved 
from the studies.
(c)   They did not compare CABG with PCI in patients 
with ITDM.
(d) They had a short-term (<1 year) follow up period.
Types of participants
All the patients suffered from T2DM and were treated 
with insulin therapy. The patients were either rand-
omized to undergo revascularization by CABG or PCI.
Outcomes and definitions
  • Adverse clinical outcomes such as all-cause mortal-
ity, stroke, MACCEs, Myocardial infarction (MI) and 
repeated or further revascularization during a long-
term follow-up period (≥1 year) were considered as 
the clinical endpoints in this study. Reported clinical 
outcomes and follow up periods have been repre-
sented in Table 1.
  • MACCEs included all-cause death, cerebrovascular 
accident (CVA), MI or repeat revascularization (sub-
sequent to PCI or CABG).
  • Stroke was defined as focal neurological deficits of 
central origin lasting >72  h, resulting in permanent 
brain damage or body impairment.
  • Death was defined as all-cause death. If data for all 
cause death was not available, data for cardiac death 
have been used.
Data extraction and quality assessment
Data were reviewed and assessed for eligibility and 
methodological quality by two authors (PKB and ZW). 
Information regarding study and patients with ITDM, 
intervention strategies, and the pre-specified clinical out-
comes reported and the corresponding follow-up periods 
was systematically extracted. Disagreements were dis-
cussed between the authors, and if the authors could not 
reach a consensus, disagreements were resolved by the 
third author (M.H.C).
The bias risk of trials was assessed with the compo-
nents recommended by the Cochrane Collaboration, 
including the following criteria: sequence generation of 
the allocation, allocation concealment, blinding of par-
ticipants, personnel, and outcome assessors, incomplete 
outcome data, selective outcome reporting, and other 
sources of bias [6]. Trials have been carefully assessed 
and a score ranging from 0 to 12 points has been allo-
cated to specific trials depending on whether they satis-
fied all the components recommended by the Cochrane 
Collaboration. Low risk of bias corresponded to a score 
of 2 in each of these 6 components whereas a score of 0 
was given if this evaluation showed a high risk of bias in 
these RCTs. A score of 1 was reserved for unclear bias. 
Therefore, if a trial showed ‘low risk bias’ in all the 6 com-
ponents recommended by the Cochrane Collaboration, a 
total score of 2 × 6 = 12 would be allocated to it.
Page 3 of 10Bundhun et al. Cardiovasc Diabetol  (2016) 15:2 
Statistical analysis
The assessment of heterogeneity across the studies was 
performed using the (a) Cochrane Q-statistic whereby 
a ‘p value’ less than 0.05 was considered statistically sig-
nificant and, (b) Cochrane I2-statistic which represented 
the percentage of the total variation across studies that 
is due to heterogeneity rather than chance whereby an I2 
value of 0 % indicated no heterogeneity, and an increased 
heterogeneity was indicated by a larger value. If I2 was 
<50 %, fixed effect was used. However, if I2 was >50 %, a 
random effect has been used. Funnel plots were assessed 
for publication bias. We calculated odd ratios (OR) and 
95 % confidence intervals (CIs) for categorical variables. 
The pooled analyses were performed with RevMan 5.3 
software.
Ethics
Ethical approval was not necessary as this study is a Sys-
tematic Review and Meta-Analysis.
Results
Study selection and general features of the included 
studies
Study selection, data collection, analysis, and reporting of 
the results were performed using the recommendations 
of the PRISMA (Preferred Reporting Items for System-
atic Reviews and Meta-Analyses) statement [7].
Six Trials (involving 10 studies) have been included in 
this meta-analysis (Table 2). During the selection process, 
20 studies comparing CABG with PCI in patients with 
T2DM were found. However, because data for patients 
with ITDM could not be retrieved from 10 studies, these 
studies had been excluded from this analysis. The flow 
diagram for the study selection has been represented in 
Fig. 1.
SYNTAX Trial, BARI Trial, FREEDOM Trial, CARDIa 
and MASS II Trials were included in this meta-analysis.
These 10 studies [2, 4, 8–15] reported long-term 
adverse clinical outcomes as their endpoints.
Patient enrollment occurred from the year 1988 to 
2010. Randomization of the patients was performed in 
different medical centers mostly from New York, England 
and Brazil.
A total number of 1,297 patients with ITDM consisting 
of 639 patients from the CABG group and 658 patients 
from the PCI group were included in this meta-analysis. 
All patients provided signed consents. General features 
of these included trials have been listed in Table 2.
Six studies reported a follow-up period of 1 year, two 
studies reported a follow-up period of 2 years, five stud-
ies reported a follow-up period of 5  years, one study 
reported a follow-up between 2 and 5 years and another 
study with a follow up period of 10  years (Table  1). To 
avoid repetition, trials were considered.
Baseline characteristics
Table 3 shows the baseline characteristics of the included 
studies. A mean age of about 60  years was observed in 
patients from both groups. With the exception of two 
studies, similar percentages of males were reported in the 
CABG and PCI groups. The percentages of hypertensive 
patients and smokers were also similar in both groups. 
Overall, there were no significant differences in the base-
line features between these patients with ITDM classified 
in the CABG or PCI group.
The bias risk scores were as follow: Seven studies were 
allocated a score of 8, two studies were allocated a score 
of 9 and one study was allocated a score of 10. These 
scores have been listed in Table 3.
Results of this meta‑analysis
The pooled analysis of these 1207 patients with ITDM 
showed CABG to be associated with a significantly 
lower long-term mortality rate with OR: 0.59, 95  % CI 
Table 1 Reported outcomes and follow up periods
MI myocardial infarction, MACCEs major adverse cerebrovascular and cardiovascular events
Studies Follow‑up (years) Clinical outcomes
Banning [8] 1 Death, MI, stent thrombosis, repeated revascularization, MACCEs
Bari [9] 5 Death
Dangas [2] 1, 5 Death, stroke, MI, repeated revascularization, MACCEs
Detre [10] 5 Death
Farkouh [11] 1, 2, 5 Death, MACCEs, MI, stroke, repeated revascularization
Kamalesh [12] 1, 2 Death, stroke, MI, repeated revascularization
Kappetein [13] 5 Death, stroke, MI, repeated revascularization, stent thrombosis
Kapur [4] 1 Death, non‑fatal MI, stroke, further revascularization, MACCEs
Lima [14] 10 Death
Soares [15] 1, 2–5 Death
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0.42–0.85; P  =  0.004. MACCEs and revascularization 
were also significantly lower in the CABG group with 
OR: 0.51, 95  % CI 0.27–0.99; P  =  0.03 and OR: 0.34, 
95 % CI 0.24–0.49; P < 0.00001 respectively. MI insignifi-
cantly favored CABG with OR: 0.75, 95 % CI 0.46–1.20; 
P  =  0.23. The rate of stroke was higher in the CABG 
Table 2 General features of the included studies
CABG coronary artery bypass surgery, PCI percutaneous coronary intervention, RCT randomized controlled trials






Banning (2010) SYNTAX RCT England – 88 88
Bari (1997) BARI RCT Pittsburgh 1988–1991 47 45
Dangas (2014) FREEDOM RCT New York 2005–2010 277 325
Detre (1999) BARI RCT Pittsburgh 1988–1991 80 78
Farkouh (2012) FREEDOM RCT New York 2005–2010 293 322
Kamalesh (2013) – RCT Indiana 2006–2010 45 48
Kappetein (2013) SYNTAX RCT Netherlands – 93 89
Kapur (2010) CARDIa RCT England – 99 88
Lima (2013) MASS II RCT Brazil 1995–2000 29 30
Soares (2006) MASS II RCT Brazil 1995–2000 23 19
Fig. 1 Flow diagram of the study selection. 456 articles were identified from Medline and EMBASE and further 11 relevant articles were identified 
through reference lists of highly selective studies. After filtering the duplicates, 360 articles were excluded since they were not related to our topic. 
46 full‑text articles were assessed for eligibility. Meta‑analyses, observational studies, and letters to editor were further eliminated (n = 26). Studies 
including data for patients with ITDM which were unable to be retrieved were also eliminated (n = 10). Finally 6 RCTs involving 10 studies were 
selected for this systematic review and meta‑analysis
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group with OR: 1.41, 95 % CI 0.64–3.09; P = 0.40. How-
ever, the result was not statistically significant. Detailed 
result of this meta-analysis has been tabulated (Table 4). 
Results for the adverse clinical outcomes between CABG 
and PCI, using a fixed effect model (I2 < 50 %) have been 
illustrated in Fig. 2. The result for MACCEs using a ran-
dom effect model (I2 > 50 %) has been illustrated in Fig. 3.
At 1 year, mortality rate was similar in both the CABG 
and the PCI groups. However, during a follow up period 
of 5  years, mortality was significantly higher in the PCI 
group with OR: 0.56, 95 % CI 0.40–0.79; P = 0.001. This 
result has been illustrated in Fig. 4.
For all of the above analyses, sensitivity analysis yielded 
consistent results. Based on a visual inspection of the 
funnel plot, there has been no evidence of publication 
bias for the included studies that assessed all clinical end-
points. The funnel plot has been represented in Fig. 5.
Discussion
Aim of this study
Several studies have shown insulin therapy to be associ-
ated with worse cardiovascular outcomes in patients with 
T2DM after revascularization with PCI [3]. However, 
data regarding the long-term adverse clinical outcomes 
in patients with ITDM revascularized by either CABG or 
PCI are still controversial and therefore, we aim to solve 
this issue in this meta-analysis.
Results of this meta‑analysis
Our results showed long-term mortality rate (9.23 % ver-
sus 14.0 %), MACCEs (15.9 versus 23.4 %) and repeated 
revascularization (7.99 versus 19.4 %) to be significantly 
lower in the CABG group compared to the PCI group. 
Mortality during a follow-up period of 5  years was also 
significantly lower in the CABG group (12.5 versus 
19.9 %). However, stroke which was higher in the CABG 
group with a percentage of 2.83 % compared to 2.01 % in 
those patients from the PCI group, was not statistically 
significant in this analysis.
Other researches supporting our study
Several studies showed similar results with this current 
meta-analysis. The systematic review and Bayesian net-
work meta-analysis comparing the long-term outcomes 
between the revascularization techniques of PCI and 
CABG in patients with T2DM also showed an increased 
association of cardiovascular outcomes in the PCI group 
and therefore, concluded that CABG seemed to be the pre-
ferred revascularization strategy in such patients especially 
if long-term survival was to be considered [16]. Another 
recent meta-analysis of several randomized controlled tri-
als comparing CABG with PCI found significantly lower 
mortality rates among patients with T2DM revascular-
ized by CABG compared to those patients revascular-
ized by PCI [17]. Moreover, the meta-analysis by Smit 
et  al. comparing CABG with PCI in patients with CAD 
showed that lower rates of death and repeated revascu-
larization were associated with CABG especially in those 
patients with T2DM, but however, CABG was associated 
with a significantly higher risk of stroke in his study [18]. 
These meta-analyses recently discussed above, compared 
revascularization by CABG and PCI in patients with CAD 
or T2DM (consisting of patients with both ITDM and 
NITDM). Our study focused only on patients with ITDM.
Is insulin therapy responsible for these adverse 
cardiovascular outcomes?
Insulin therapy could be one of the reasons responsi-
ble for the increased adverse cardiovascular outcomes 
among patients who underwent revascularization pro-
cedures (including both CABG and PCI). Even if the 
study by Marso et  al. showed no significant differences 
Table 3 Baseline characteristics of the included studies
HT hypertension, Cs current smoker
Trials Age 
(years)
Males (%) HT (%) Cs (%) Cochrane
CABG/PCI CABG/PCI CABG/PCI CABG/PCI Bias score
Banning [8] 65.4/65.4 71.0/71.0 69.9/69.9 15.8/15.8 8
Bari (1997) 62.5/62.1 58.0/56.0 66.0/65.0 – 9
Dangas [2] 62.6/62.6 61.3/6.3 87.5/87.5 17.9/17.9 8
Detre [10] 62.3/62.3 57.0/57.0 65.0/65.0 65.0/65.0 9
Farkouh [11] 63.1/63.2 69.5/73.2 – 16.6/14.8 8
Kamalesh 
[12]
62.1/62.7 99.0/99.0 95.7/96.0 20.6/27.7 8
Kappetein 
[13]
65.4/65.4 71.0/71.0 70.0/70.0 16.0/16.0 8
Kapur [4] 63.6/64.3 77.9/70.7 76.6/76.6 24.6/24.6 10
Lima [14] 59.0/61.0 72.0/56.0 71.0/72.0 34.0/17.0 8
Soares [15] 60.0/61.0 67.0/54.0 73.0/73.0 – 8
Table 4 Result of this meta-analysis
MI myocardial infarction, MACCEs major adverse cerebrovascular and 





OR, 95 % CI P value I2 %
Mortality 6 0.59 [0.42, 0.85] 0.004 4
MI 4 0.75 [0.46, 1.20] 0.23 26
MACCEs 3 0.51 [0.27, 0.99] 0.03 72
Stroke 4 1.41 [0.64, 3.09] 0.40 0
Revascularization 5 0.34 [0.24, 0.49] <0.00001 38
Mortality at 1 year 5 1.07 [0.52, 2.19] 0.86 0
Mortality during 
5 years
4 0.56 [0.40, 0.79] 0.001 0
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in treatment effect between CABG and PCI in patients 
with T2DM, the author concluded that insulin therapy 
remained an independent risk of adverse outcomes in 
patients with T2DM [19]. Moreover, the prospective reg-
istry data of consecutive CABG patients reported mor-
tality to be significantly higher in patients with T2DM 
treated with insulin therapy, compared to those patients 
not treated with insulin, or NDM patients [20].
However, insulin therapy is expected to be only partly 
responsible for these adverse clinical events after revas-
cularization. The review published by Lee et  al. which 
showed a significantly lower rate of mortality and 
Fig. 2 Forest plot comparing the adverse clinical outcomes between the CABG and PCI groups
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MACCEs among patients with T2DM in the CABG 
group, concluded that insulin therapy did not affect the 
clinical outcomes reported in these two revascularization 
procedures [21]. Also, the study by Liu et al. showed an 
increased level of HBA1c to be an independent predic-
tor of MACCEs in similar patients [22]. Furthermore, the 
study by Lopez de Andres et al. showed a higher comor-
bidity and the female gender to be associated with a high 
rate of in-hospital mortality in patients with T2DM and 
NDM [23]. Patients with T2DM often exhibit increased 
platelet reactivity despite combined treatment with clopi-
dogrel and aspirin after PCI [24]. Patients with ITDM 
requiring prasugrel after PCI also have higher platelet 
reactivity compared to patients with NITDM or those 
without T2DM. This could also contribute to a higher 
risk of cardiovascular outcomes after revascularization 
procedures. However, our study was different since it 
compared CABG and PCI in patients with ITDM.
Fig. 3 Forest plot comparing major adverse cardiovascular and cerebrovascular events between the CABG and PCI groups
Fig. 4 Forest plot comparing mortality at 1 and 5 years between the CABG and PCI groups
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Other researches with different results from our 
meta‑analysis
Other studies showed different results compared to ours. 
For example, the study by Gargiolo et  al. comparing the 
5 years clinical outcomes between CABG and PCI showed 
no statistical difference in mortality, MI and stroke 
between CABG and PCI but showed repeated revascular-
ization which was significantly increased in the PCI group 
[25]. However, his study only included patients with left 
main coronary artery disease. Another study, by Hallberg 
et al. which assessed the association of DM with 16 years 
survival after revascularization by CABG showed patients 
without DM to have a similar survival rate with the other 
patients, while the mortality rate in patients with T2DM 
started to increase a few years post-CABG [26]. Apart 
from showing that DM was associated with an increased 
risk of mortality after CABG, his study also showed an 
even higher cardiovascular cause of mortality in patients 
with ITDM compared to those without insulin therapy 
but however, the study did not compare the adverse cardi-
ovascular outcomes between CABG and PCI. Moreover, 
Naito et al. compared the mortality rate between CABG 
and PCI in elderly patients with T2DM complicated with 
multi-vessel coronary disease and showed no significant 
difference in the mortality rate between CABG and PCI 
[27]. But the author stated that the CABG group had 
more patients with complex coronary lesions which could 
be responsible for such an outcome.
Even if the rate of stroke was not statistically significant 
in our study, a few other RCTs have reported a significant 
increased risk of stroke in those patients revascularized 
by CABG compared to PCI. However, all these studies 
were not powerful enough to examine strict differences 
in the risk of stroke. Two prior meta-analyses have ana-
lyzed the risk of stroke post-CABG or post-PCI, with 
conflicting results [28, 29]. But, another meta-analysis 
including 19 trials with 10,944 patients randomized to 
CABG and PCI showed a real association of an increased 
risk of stroke at 30  days and at mid-term follow up in 
the CABG group compared to the PCI group [30]. Post-
CABG versus post-PCI stroke rates (post-CABG stroke 
rate at 1  year was 1.83  %; with OR 1.67). Nevertheless, 
the increased stroke rate following CABG compared to 
PCI was independent of ITDM status (reported as 5-year 
rates of 7.5 vs. 3.7 % for CABG and PCI in patients with 
ITDM; and 4.3 vs. 1.7 % for CABG and PCI in patients 
with NITDM) and could mean an association of stroke 
with CABG and not with the insulin therapy.
Novelty in this study
This study has strictly been conducted in patients with 
ITDM. Several studies have compared CABG with PCI in 
Fig. 5 Funnel plot assessing publication bias
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patients with CAD or T2DM (including a combination of 
patients with both ITDM and NITDM). However, since 
patients with ITDM are more complicated patients with 
several co-morbidities, we have conducted a meta-anal-
ysis on this particular population of patients with T2DM.
Finally, similar to the FREEDOM trial which clearly 
showed revascularization by CABG to be superior com-
pared to PCI in patients with T2DM, our study which 
also showed CABG to be better than PCI in patients with 
ITDM, also suggests a comparative analysis of the new 
incoming stents which warrant further research [31].
Our study is expected to satisfy all the requirements 
for a meta-analysis, in terms of low heterogeneity in 
almost all of the different subgroups, absent publication 
bias, and sensitivity analysis, and provides robust scien-
tific validity to our findings, which can assist informed 
decision making by patients and physicians when decid-
ing on the optimal strategy for revascularization in CAD 
patients with ITDM.
Limitation
Due to the small population size, the result of this study 
could be restricted to an extent. Moreover, these RCTs 
included patients with ITDM with different clinical con-
ditions or complications. For example, the CARDia and 
FREEDOM trials included patients with symptomatic 
multi-vessel CAD and multi-vessel CAD with or with-
out symptoms respectively whereas the SYNTAX trial 
included patients with left main coronary disease and/
or three vessel disease. The BARI trial included patients 
with severe CAD. Variable degree of complications in 
these patients could have an effect on our results. How-
ever, despite these limitations, our data point to the 
urgent need for comprehensive comparison between 
these two revascularization strategies.
Conclusion
Compared to PCI, CABG was associated with a sig-
nificantly lower mortality rate, MACCEs and repeated 
revascularization during this long-term follow up period 
in patients with ITDM. However, even if a higher rate of 
stroke in the CABG group was not statistically significant 
in our result, new researches with larger number of ran-
domized patients are required to completely solve this 
issue.
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